We are live on ! Find out more
RADX

Radiopharm Theranostics
RADX

7 hedge funds and large institutions have $2.06M invested in Radiopharm Theranostics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

641.94% more ownership

Funds ownership: 8.91% → 650.86% (+642%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

36% less funds holding

Funds holding: 11 → 7 (-4)

44% less capital invested

Capital invested by funds: $3.67M → $2.06M (-$1.61M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
7
Holders Change
-4
Holders Change %
-36.36%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$248M
2
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$562

Top Sellers

Rank Fund Capital Flow
1
HSBC Holdings
HSBC Holdings
United Kingdom
-$637K
2
RP
Regal Partners
Australia
-$248K
3
VF
Virtu Financial
New York
-$76K
4
Jane Street
Jane Street
New York
-$75.5K
5
UBS Group
UBS Group
Switzerland
-$55.1K

RADX Hedge Fund Activity: Q1 2026 in Review

7 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q1 2026, worth a combined $2.06M — down 44% from $3.67M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of RADX and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Stonepine Capital Management, adding an estimated $248M. The largest seller was HSBC Holdings, cutting an estimated $637K.

  • 7 institutional investors held Radiopharm Theranostics (RADX) as of Q1 2026, down from 11 in Q4 2025.
  • Funds reported $2.06M of Radiopharm Theranostics stock for Q1 2026, down 44% quarter-over-quarter.
  • 0 funds opened new Radiopharm Theranostics positions in Q1 2026 and 4 closed out, a net change of -4 holders.
  • The largest Radiopharm Theranostics buyer in Q1 2026 was Stonepine Capital Management, an estimated $248M added.
  • The largest Radiopharm Theranostics seller in Q1 2026 was HSBC Holdings, an estimated $637K sold.

Based on aggregated 13F filings for Q1 2026.